| Identification | More | [Name]
2',3',5'-Tri-O-acetyluridine | [CAS]
4105-38-8 | [Synonyms]
2',3',5'-TRIACETYLURIDINE
2',3',5'-TRI-O-ACETYLURIDINE
TAU
URIDINE 2',3',5'-TRIACETATE
2`,3`,5`-Tracetyluridine
2',3',5'-Tri-O-acetyl-D-uridine
2'', 3'', 5''-TRIACETYLURIDINE (2'', 3'', 5''-TRI-O-ACETYLURIDINE)
1-(2-O,3-O,5-O-Triacetyl-β-D-ribofuranosyl)-4-hydroxypyrimidine-2(1H)-one | [EINECS(EC#)]
223-881-5 | [Molecular Formula]
C15H18N2O9 | [MDL Number]
MFCD00023795 | [Molecular Weight]
370.31 | [MOL File]
4105-38-8.mol |
| Chemical Properties | Back Directory | [Melting point ]
127.0 to 131.0 °C | [density ]
1.43±0.1 g/cm3(Predicted) | [storage temp. ]
−20°C
| [solubility ]
Chloroform (Slightly), Dichloromethane (Slightly), DMSO (Slightly) | [form ]
Solid | [pka]
9.39±0.10(Predicted) | [color ]
Off-White | [InChI]
InChI=1S/C15H18N2O9/c1-7(18)23-6-10-12(24-8(2)19)13(25-9(3)20)14(26-10)17-5-4-11(21)16-15(17)22/h4-5,10,12-14H,6H2,1-3H3,(H,16,21,22)/t10-,12-,13-,14-/m1/s1 | [InChIKey]
AUFUWRKPQLGTGF-QRMSVCKNSA-N | [SMILES]
C(OC(=O)C)[C@H]1O[C@@H](N2C=CC(=O)NC2=O)[C@H](OC(=O)C)[C@@H]1OC(=O)C | [CAS DataBase Reference]
4105-38-8(CAS DataBase Reference) |
| Hazard Information | Back Directory | [Description]
Uridine
triacetate is an orally available pro-drug of uridine approved by
the FDA for the treatment of the rare autosomal recessive
disorder called hereditary orotic aciduria. The drug was also
approved for treating overdose of two chemotherapies
(fluorouracil and capecitabine). Uridine triacetate was
developed by Wellstat Therapeutics and licensed to BTG. | [Chemical Properties]
White or almost white crystalline powder | [Uses]
2’,3’,5’-Triacetyluridine is used in the treatment of Alzheimer’s disease in mice and provide neuroprotective effects. Shown to also decrease depressive symptoms and increases in brain pH bipolar patients. | [Definition]
ChEBI: An acetate ester that is uracil in which the three hydroxy hydrogens are replaced by acetate group. A prodrug for uridine, it is used for the treatment of hereditary orotic aciduria and for management of fluorouracil toxicity. | [Synthesis]
Commercially available uridine (167) was treated with acetic
anhydride in the presence of catalytic boron trifluoride-etherate,
and the crude product was recrystallized from ethanol to give
uridine triacetate (XX) in 74-78% yield.
 | [storage]
Store at -20°C |
|
|